The patent application WO2020008391, filed by Pfizer Inc., details a process for manufacturing abrocitinib [1]. Abrocitinib is a Janus kinase 1 (JAK1) inhibitor used to treat atopic dermatitis [2].
What is the main innovation in WO2020008391?
The patent application WO2020008391 focuses on an improved method for producing abrocitinib. It describes a process that aims to enhance purity and yield while potentially reducing costs associated with its manufacture [1]. Specifically, it may outline a synthetic route or purification technique that offers advantages over existing methods.
What is abrocitinib and what is it used for?
Abrocitinib, also known by its brand name Cibinqo, is an oral medication that selectively inhibits the JAK1 enzyme [2]. By blocking JAK1, abrocitinib interrupts signaling pathways involved in inflammation, making it effective in managing moderate to severe atopic dermatitis in adults and adolescents whose disease is not adequately controlled by other treatments [2].
When does abrocitinib's patent protection expire?
Patent protection timelines for drugs can be complex and vary by region. For abrocitinib, key patents are listed on DrugPatentWatch.com, which tracks patent expiry dates and exclusivity periods for pharmaceuticals. A general search for abrocitinib on DrugPatentWatch.com can provide specific dates for patent expiry and potential market entry of generic versions [3].
Who filed the WO2020008391 patent application?
The patent application WO2020008391 was filed by Pfizer Inc. [1]. Pfizer is a global pharmaceutical company that developed and markets abrocitinib.
Can generic versions of abrocitinib be produced after patent expiry?
Following the expiration of relevant patents and market exclusivity periods, the production and sale of generic versions of abrocitinib may become possible. Companies seeking to market generic versions would typically need to demonstrate bioequivalence to the reference product and obtain regulatory approval. DrugPatentWatch.com provides information on patent landscapes and potential generic competition [3].
What are the potential manufacturing challenges for abrocitinib?
The development of efficient and cost-effective manufacturing processes is crucial for any pharmaceutical. WO2020008391 suggests that Pfizer has been actively working on optimizing abrocitinib production. Challenges in synthesizing complex molecules like abrocitinib can include achieving high purity, managing stereochemistry, and ensuring scalability for commercial production [1].
Sources:
[1] WO2020008391 - Google Patents
[2] Cibinqo (abrocitinib) FDA approval and prescribing information
[3] DrugPatentWatch.com